NL301149I1 - - Google Patents
Info
- Publication number
- NL301149I1 NL301149I1 NL301149C NL301149C NL301149I1 NL 301149 I1 NL301149 I1 NL 301149I1 NL 301149 C NL301149 C NL 301149C NL 301149 C NL301149 C NL 301149C NL 301149 I1 NL301149 I1 NL 301149I1
- Authority
- NL
- Netherlands
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792440P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/029421 WO2014144842A2 (en) | 2013-03-15 | 2014-03-14 | Pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL301149I1 true NL301149I1 (enExample) | 2021-12-08 |
| NL301149I2 NL301149I2 (nl) | 2022-11-24 |
Family
ID=50732290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301149C NL301149I2 (nl) | 2013-03-15 | 2021-12-06 | setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11129869B2 (enExample) |
| EP (2) | EP2970389B1 (enExample) |
| JP (4) | JP6538025B2 (enExample) |
| KR (1) | KR102378943B1 (enExample) |
| CN (3) | CN105518021A (enExample) |
| AU (5) | AU2014228460B2 (enExample) |
| BR (1) | BR112015023409B1 (enExample) |
| CA (2) | CA3209602A1 (enExample) |
| DK (1) | DK2970389T3 (enExample) |
| ES (1) | ES2825076T3 (enExample) |
| FR (1) | FR21C1059I2 (enExample) |
| IL (2) | IL288961B1 (enExample) |
| NL (1) | NL301149I2 (enExample) |
| NO (1) | NO2021051I1 (enExample) |
| PL (1) | PL2970389T3 (enExample) |
| PT (1) | PT2970389T (enExample) |
| RU (1) | RU2690377C2 (enExample) |
| WO (1) | WO2014144842A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3301962A1 (en) | 2011-12-29 | 2026-03-02 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers |
| US10196425B2 (en) * | 2013-03-15 | 2019-02-05 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
| PT2970389T (pt) | 2013-03-15 | 2020-10-21 | Rhythm Pharmaceuticals Inc | Composições farmacêuticas |
| WO2014169256A2 (en) | 2013-04-11 | 2014-10-16 | Vanderbilt University | Polyplexes |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| PT3356386T (pt) | 2015-09-30 | 2024-05-17 | Rhythm Pharmaceuticals Inc | Método de tratamento de distúrbios associados à via do receptor da melanocortina-4 |
| JP6701572B2 (ja) * | 2016-07-05 | 2020-05-27 | 株式会社リコー | インク、収容容器、画像形成方法及び画像形成装置 |
| IL265109B2 (en) | 2016-09-13 | 2024-05-01 | Allergan Inc | Stabilized non-protein clostridial toxin compositions |
| JP2020514365A (ja) | 2017-03-15 | 2020-05-21 | ノヴォ ノルディスク アー／エス | メラノコルチン４受容体に結合可能な二環式化合物 |
| HUE066356T2 (hu) | 2017-08-24 | 2024-07-28 | Novo Nordisk As | GLP-1 készítmények és alkalmazásaik |
| AR113885A1 (es) | 2017-11-15 | 2020-06-24 | Rhythm Pharmaceuticals Inc | Formulaciones de péptidos de liberación sostenida |
| WO2019219714A1 (en) | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Compounds capable of binding to melanocortin 4 receptor |
| WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
| KR102087634B1 (ko) * | 2018-10-11 | 2020-03-11 | (주)바이텍 | 항비만용 조성물 |
| KR20210116505A (ko) * | 2019-01-04 | 2021-09-27 | 키네타 크로닉 페인, 엘엘씨 | 코노톡신 펩티드 유사체 및 통증 및 염증성 병태의 치료를 위한 용도 |
| PE20221575A1 (es) | 2020-02-18 | 2022-10-06 | Novo Nordisk As | Formulaciones farmaceuticas |
| CN111718408A (zh) * | 2020-07-06 | 2020-09-29 | 成都圣诺生物制药有限公司 | 一种Setmelanotide的制备方法 |
| EP4392072A4 (en) * | 2021-08-24 | 2026-03-04 | Univ Michigan Regents | MC4R AGONIST PEPTIDES |
| KR20230065921A (ko) * | 2021-11-05 | 2023-05-12 | (주)아이엠디팜 | 신규한 서방성 지질 전구 제제 및 이를 포함하는 서방성 주사용 약학 조성물 |
| WO2023247999A1 (en) * | 2022-06-24 | 2023-12-28 | Mainline Biosciences (Shanghai) Co., Ltd. | Peptidic pain modulators and methods for producing and using the same |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849704A (en) * | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
| WO1994026251A1 (en) * | 1993-05-07 | 1994-11-24 | Sequus Pharmaceuticals, Inc. | Subcutaneous liposome delivery method |
| US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5731408A (en) * | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
| US20070185032A1 (en) | 1996-12-11 | 2007-08-09 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US5968895A (en) * | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US7176279B2 (en) * | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
| JP2005504715A (ja) * | 2000-12-29 | 2005-02-17 | アドバンスト インハレーション リサーチ，インコーポレイテッド | 持続放出特性を有する吸入用粒子 |
| CA2453515A1 (en) | 2001-07-11 | 2003-01-23 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptides |
| US20040097419A1 (en) * | 2002-11-19 | 2004-05-20 | Holger Petersen | Organic compounds |
| FR2851563B1 (fr) | 2003-02-26 | 2005-04-22 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
| FR2852957B1 (fr) | 2003-03-31 | 2005-06-10 | Sod Conseils Rech Applic | Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament |
| AU2004251616A1 (en) * | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Melanocortin receptor 4(MC4) agonists and their uses |
| FR2862971B1 (fr) | 2003-11-28 | 2006-03-24 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
| KR100638041B1 (ko) * | 2003-12-24 | 2006-10-23 | 주식회사 삼양사 | 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법 |
| FR2872165B1 (fr) | 2004-06-24 | 2006-09-22 | Sod Conseils Rech Applic | Nouveaux derives de pyrimido-benzimidazole |
| AU2006269321A1 (en) | 2005-07-08 | 2007-01-18 | Ipsen Pharma S.A.S. | Ligands of melanocortin receptors |
| KR100997177B1 (ko) | 2005-07-08 | 2010-11-29 | 입센 파마 에스.에이.에스 | 멜라노코르틴 수용체 리간드 |
| EP2148692B1 (en) | 2007-05-25 | 2017-01-25 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
| EP2167112A4 (en) | 2007-06-15 | 2012-01-25 | Ipsen Pharma Sas | CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS |
| TR201815292T4 (tr) | 2007-11-05 | 2018-11-21 | Board Of Supervisors Of Louisiana State Univ And Agriculture And Mechanical College | İnsüli̇n duyarliliğinin tedavi̇si̇nde melanokorti̇nleri̇n kullanimi. |
| TW201002340A (en) * | 2008-06-09 | 2010-01-16 | Palatin Technologies Inc | Melanocortin receptor-specific peptides for treatment of obesity |
| UA104866C2 (uk) * | 2008-06-25 | 2014-03-25 | Ендо Фармас'Ютікалз Солюшнз Інк. | Імплантат октреотиду, який містить вивільняючу речовину |
| CN101439182B (zh) | 2008-12-18 | 2012-02-01 | 北京大学 | 一种生长抑素受体介导的肿瘤靶向药物组合物 |
| EA020959B1 (ru) * | 2009-06-08 | 2015-03-31 | Палатин Текнолоджиз, Инк. | Пептиды, специфичные к меланокортиновым рецепторам |
| UY32690A (es) * | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| KR20120059520A (ko) | 2009-08-05 | 2012-06-08 | 입센 파마 에스.에이.에스 | 이상지질혈증을 치료하기 위한 멜라노코르틴의 용도 |
| US9314509B2 (en) | 2009-11-16 | 2016-04-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
| JP2013510881A (ja) | 2009-11-16 | 2013-03-28 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | Ａｃ−Ａｒｇ−シクロ（Ｃｙｓ−Ｄ−Ａｌａ−Ｈｉｓ−Ｄ−Ｐｈｅ−Ａｒｇ−Ｔｒｐ−Ｃｙｓ）−ＮＨ２の合成のための方法 |
| BR112013027222B1 (pt) | 2011-06-14 | 2022-07-12 | Ipsen Pharma S.A.S. | Composição de liberação sustentada que contém peptídeos como ingrediente ativo |
| JP2013046596A (ja) * | 2011-08-29 | 2013-03-07 | Alpha-Nano-Medica Co Ltd | 新規な複合体、それを含有する医薬及び癌の治療方法 |
| WO2013033838A1 (en) * | 2011-09-09 | 2013-03-14 | Pharmagap Inc. | Liposomal formulations of cationic peptides and uses thereof |
| EP2705835A1 (en) | 2012-06-08 | 2014-03-12 | Ipsen Pharma S.A.S. | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
| PT2970389T (pt) | 2013-03-15 | 2020-10-21 | Rhythm Pharmaceuticals Inc | Composições farmacêuticas |
| US10196425B2 (en) * | 2013-03-15 | 2019-02-05 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
-
2014
- 2014-03-14 PT PT147245740T patent/PT2970389T/pt unknown
- 2014-03-14 IL IL288961A patent/IL288961B1/en unknown
- 2014-03-14 CA CA3209602A patent/CA3209602A1/en active Pending
- 2014-03-14 CN CN201480026783.9A patent/CN105518021A/zh active Pending
- 2014-03-14 EP EP14724574.0A patent/EP2970389B1/en active Active
- 2014-03-14 ES ES14724574T patent/ES2825076T3/es active Active
- 2014-03-14 WO PCT/US2014/029421 patent/WO2014144842A2/en not_active Ceased
- 2014-03-14 BR BR112015023409-7A patent/BR112015023409B1/pt active IP Right Grant
- 2014-03-14 KR KR1020157029620A patent/KR102378943B1/ko active Active
- 2014-03-14 US US14/775,911 patent/US11129869B2/en active Active
- 2014-03-14 AU AU2014228460A patent/AU2014228460B2/en active Active
- 2014-03-14 RU RU2015143965A patent/RU2690377C2/ru active
- 2014-03-14 DK DK14724574.0T patent/DK2970389T3/da active
- 2014-03-14 EP EP20185463.5A patent/EP3778623A1/en active Pending
- 2014-03-14 CN CN202211043877.XA patent/CN115957297A/zh active Pending
- 2014-03-14 JP JP2016503089A patent/JP6538025B2/ja active Active
- 2014-03-14 CA CA2906782A patent/CA2906782C/en active Active
- 2014-03-14 CN CN202211043853.4A patent/CN115957296A/zh active Pending
- 2014-03-14 PL PL14724574T patent/PL2970389T3/pl unknown
-
2015
- 2015-09-09 IL IL241378A patent/IL241378B/en unknown
-
2019
- 2019-01-08 AU AU2019200101A patent/AU2019200101B2/en active Active
- 2019-06-05 JP JP2019104944A patent/JP2019189619A/ja active Pending
-
2021
- 2021-04-30 AU AU2021202699A patent/AU2021202699A1/en not_active Abandoned
- 2021-08-13 US US17/401,929 patent/US12285460B2/en active Active
- 2021-12-03 NO NO2021051C patent/NO2021051I1/no unknown
- 2021-12-06 NL NL301149C patent/NL301149I2/nl unknown
- 2021-12-14 FR FR21C1059C patent/FR21C1059I2/fr active Active
-
2022
- 2022-02-17 JP JP2022023265A patent/JP2022065117A/ja active Pending
-
2023
- 2023-07-12 AU AU2023204625A patent/AU2023204625A1/en not_active Abandoned
-
2024
- 2024-09-27 JP JP2024169338A patent/JP2025004067A/ja active Pending
-
2025
- 2025-03-31 US US19/096,163 patent/US20260053885A1/en active Pending
- 2025-08-05 AU AU2025213562A patent/AU2025213562A1/en active Pending